Want to see TSE:FRX full AI Analyst Report?
Fennec Pharmaceuticals (FRX) Financial Statements
Fennec Pharmaceuticals Financial Overview
Fennec Pharmaceuticals's market cap is currently $501.81M. The company's EPS TTM is $-0.13; its P/E ratio is -78.77; Fennec Pharmaceuticals is estimated to report earnings on November 5, 2026, and the estimated EPS forecast is $0.13. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 44.64M | $ 47.54M | $ 21.25M | $ 1.53M | $ 0.00 |
| Gross Profit | $ 40.88M | $ 44.35M | $ 19.99M | $ 1.45M | $ 0.00 |
| Operating Income | $ -6.35M | $ 2.48M | $ -13.06M | $ -22.74M | $ -17.22M |
| EBITDA | $ -7.45M | $ 4.80M | $ -12.36M | $ -22.59M | $ -17.22M |
| Net Income | $ -9.74M | $ -436.00K | $ -16.05M | $ -23.71M | $ -17.35M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 36.72M | $ 26.63M | $ 13.27M | $ 23.77M | $ 21.10M |
| Total Assets | $ 70.07M | $ 44.95M | $ 26.86M | $ 26.94M | $ 22.41M |
| Total Debt | $ 0.00 | $ 19.34M | $ 30.95M | $ 24.90M | $ 4.99M |
| Net Debt | $ -36.72M | $ -7.29M | $ 17.68M | $ 1.13M | $ -16.11M |
| Total Liabilities | $ 35.02M | $ 50.82M | $ 38.49M | $ 29.51M | $ 6.64M |
| Stockholders' Equity | $ 35.05M | $ -5.87M | $ -11.62M | $ -2.57M | $ 15.77M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.47M | $ 26.98M | $ -17.14M | $ -18.06M | $ -14.22M |
| Operating Cash Flow | $ -12.47M | $ 26.98M | $ -17.14M | $ -18.06M | $ -14.22M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 22.63M | $ -13.62M | $ 6.64M | $ 20.73M | $ 4.98M |
Currency in USD